ArticleScientific reports2025
Targeted neuroprotection with OX26-functionalized Epigallocatechin-3-gallate (EGCG)-stabilized se nanoparticles in a rat model of cerebral ischemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A UHPLC-Orbitrap-MS Metabolomics Strategy Reveals Glycerophospholipid Metabolic Remodeling Is Associated with the Anti-Arthritic Effect of Glycyrrhiza Protein-Paeoniflorin Nanoparticles via PI3K/AKT/NLRP3 Axis.Molecules (Basel, Switzerland) · 2026Article
- Catechins in stroke: multi-target mechanisms, preclinical evidence, and translational challenges.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Stroke remains one of the leading causes of death and long-term disability worldwide, underscoring the need for innovative therapeutic approaches. Smart drug delivery systems employing nanoparticles functionalized with targeting ligands and therapeutic agents offer promising strategies for mitigating cerebral ischemic damage. In this study, a multifunctional brain-targeted nanocarrier (OX26-MK801-EGCG@Se NPs) was designed and synthesized by stabilizing selenium nanoparticles (Se NPs) with epigallocatechin gallate (EGCG), conjugating the NMDA receptor antagonist MK-801, and functionalizing the surface with the transferrin receptor-targeting monoclonal antibody OX26. Nanoparticles were synthesized via the reduction of selenious acid using ascorbic acid in the presence of EGCG, followed by PEG-carboxylic acid-mediated conjugation of MK-801 and OX26. Structural and physicochemical characterization was conducted using scanning transmission electron microscopy (STEM), dynamic light scattering (DLS), zeta potential analysis, Fourier-transform infrared spectroscopy (FTIR), and energy-dispersive X-ray spectroscopy (EDX). In vivo experiments were carried out on 68 male Wistar rats randomly assigned to Sham, Ischemia/Reperfusion (IR), IR + OX26-EGCG@Se NPs, and IR + OX26-MK801-EGCG@Se NPs groups. A transient middle cerebral artery occlusion (MCAO) model was established with 90-min occlusion followed by 72-h reperfusion. Nanoparticles (1000 µg/mL) were administered intraperitoneally 1 h prior to ischemia induction. Behavioral assessments included the open field and novel object recognition tests. Brain tissue was then analyzed for glutamate and Ca levels (ELISA), infarct volume (TTC staining), and NMDAR1, NMDAR2A, and AMPAR1 expression (immunohistochemistry). The findings revealed that both nanoparticle treatments significantly improved motor and cognitive outcomes, reduced glutamate and Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.